NCT06111235 Phase 3 Active not recruiting
A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT Study sponsor: CG Oncology, Inc. · CGON
Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.
Changes Study details Primary completion 2026-11 Estimated
Enrollment · participants 367 Actual
Source updated 2026-07-01 Last update listed in the registry record
Version history
Changes to this trial Last 12 months
This database covers selected trials and recorded edits. Some past edits may be missing, and saved text about the main study measures (endpoints) may be shortened. Check the original registry record when a detail matters. Read our methodology